DL-norvaline → Tylosin

HRID 1395066

반응식

N[C@H](C(O)=O)CC(C)C.NC(C(O)=O)CCC.[CH3:18][CH2:19][C@H:20]1[O:37][C:35](=[O:36])[CH2:34][C@@H:33]([O:38]C(C)=O)[C@H:32]([CH3:42])[C@@H:31]([O:43][C@@H:44]2[O:49][C@H:48]([CH3:50])[C@@H:47]([O:51][C@@H:52]3[O:57][C@@H:56]([CH3:58])[C@H:55]([O:59]C(CC(C)C)=O)[C@@:54]([OH:67])([CH3:66])[CH2:53]3)[C@H:46]([N:68]([CH3:70])[CH3:69])[C@H:45]2[OH:71])[C@@H:30]([CH2:72][CH:73]=[O:74])[CH2:29][C@@H:28]([CH3:75])[C:26](=[O:27])[CH:25]=[CH:24][C:23]([CH3:76])=[CH:22][C@@H:21]1[CH2:77][O:78][C@@H:79]1[O:84][C@H:83]([CH3:85])[C@@H:82]([OH:86])[C@@H:81]([O:87][CH3:88])[C@H:80]1[O:89][CH3:90]>>[CH3:18][CH2:19][C@H:20]1[O:37][C:35](=[O:36])[CH2:34][C@@H:33]([OH:38])[C@H:32]([CH3:42])[C@@H:31]([O:43][C@@H:44]2[O:49][C@H:48]([CH3:50])[C@@H:47]([O:51][C@@H:52]3[O:57][C@@H:56]([CH3:58])[C@H:55]([OH:59])[C@@:54]([OH:67])([CH3:66])[CH2:53]3)[C@H:46]([N:68]([CH3:70])[CH3:69])[C@H:45]2[OH:71])[C@@H:30]([CH2:72][CH:73]=[O:74])[CH2:29][C@@H:28]([CH3:75])[C:26](=[O:27])[CH:25]=[CH:24][C:23]([CH3:76])=[CH:22][C@@H:21]1[CH2:77][O:78][C@@H:79]1[O:84][C@H:83]([CH3:85])[C@@H:82]([OH:86])[C@@H:81]([O:87][CH3:88])[C@H:80]1[O:89][CH3:90]

참가 물질

반응물 3

HCID 824DL-norvaline

HCID 6106L-Leucine

HCID 6441094Tylvalosin

생성물 1

HCID 5280440Tylosin

실험 절차

The conversion reaction was carried out in a manner similar to Example 4 with the same strain, in which L-leucine was used in substitution for DL-norvaline in Example 4 as the isovaleryl donor. About 400 mg of white crystals of 3-acetyl-4"-isovaleryltylosin were obtained from 3 g of tylosin.

후처리

customThe conversion reaction

출처 및 근거

ORD 기록: ord-7e8c95e9140d4855b3d9000be1df22a2
출처 데이터셋: uspto-grants-1980_05
DOI: 10.6084/m9.figshare.5104873.v1
특허 번호: US04201843

연결된 노트

불러오는 중…